Adamis Pharmaceuticals Corporation Earnings in line, Revenue Beats In Q3

Investing.com - Adamis Pharmaceuticals Corporation reported on Monday third quarter earnings that matched analysts' forecasts and revenue that topped expectations.

Adamis Pharmaceuticals Corporation announced earnings per share of $-0.0300 on revenue of $1.51M. Analysts polled by Investing.com anticipated EPS of $-0.0300 on revenue of $500K.

Adamis Pharmaceuticals Corporation shares are down 30% from the beginning of the year, still down 83.33% from its 52 week high of $1.08 set on November 16, 2021.

h2 Adamis Pharmaceuticals Corporation follows other major Healthcare sector earnings this month/h2

Adamis Pharmaceuticals Corporation's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.

Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar